Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review

Published:2020-03-09 Issue:4 Volume:19 Page:459-466
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Reynolds Kelly A.¹^ORCID,Pithadia Deeti J²,Lee Erica B³,Han George⁴,Wu Jashin J⁵

Affiliation:

1. Department of Dermatology, Univeristy of Cincinnati College of Medicine, Cincinnati, OH, USA

2. Medical College of Georgia, Augusta University, Augusta, GA, USA

3. Department of Medicine, Santa Barbara Cottage Hospital, Santa Barbara, CA, USA

4. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

5. Dermatology Research and Education Foundation, Irvine, CA, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2020.1737674

Reference36 articles.

1. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice

2. Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future

3. Biosimilars in psoriasis: What can we expect?

4. Biosimilars for psoriasis: preclinical analytical assessment to determine similarity

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and emerging prospects in the psoriatic treatment;International Immunopharmacology;2023-07

2. Biosimilars approved for psoriasis treatment in Europe;PONS - medicinski casopis;2023

3. Biosimilars;TURKDERM;2022-05-05

4. Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis;JAMA Dermatology;2021-06-01

5. Making the switch: a retrospective case series of our departmental experience of biosimilar medications;International Journal of Dermatology;2021-02-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3